Her-2/neu和COX-2在卵巢上皮性肿瘤的表达变化及意义

目的探讨卵巢上皮性肿瘤组织中Her-2/neu和COX-2蛋白的表达水平与卵巢癌临床病理因素及患者预后的关系。方法采用免疫组织化学方法检测60例卵巢上皮性癌,20例卵巢良性肿瘤和20例正常卵巢组织中Her-2/neu和COX-2蛋白的表达状况,研究它们的表达与临床病理特征的关系。结果 Her-2/neu在上皮性卵巢癌组织的阳性表达率明显高于卵巢良性肿瘤组织和正常卵巢组织,差异有统计学意义(P<0.05),在恶性肿瘤组中,Her-2/neu高表达率在临床Ⅲ/Ⅳ期明显高于Ⅰ/Ⅱ期,有淋巴结转移明显高于无淋巴结转移(P<0.05);卵巢癌组织中COX-2表达率明显高于良性卵巢肿瘤(P<0.05),COX-2在正常卵巢组织中无表达。在恶性肿瘤组中,COX-2在有淋巴结转移明显高于无淋巴结转移(P<0.05);Her-2/neu表达与COX-2表达存在正相关性(r=0.295,P=0.022)。结论 Her-2/neu和COX-2蛋白在卵巢上皮性癌的表达升高,可能导致细胞增殖失控,为卵巢上皮性癌的诊断及预后评价提供参考。

Expression and clinical significance of Her-2/neu and COX-2 in epithelial ovarian tumors

Objective To investigate the expression and clinical significance of Her-2/neu and COX-2 in epithelial ovarian tumors,and to explore the correlation between their expression levels and clinical pathological factors as well as patients＇ prognosis.Methods The expressions of Her-2/neu and COX-2 were detected by immunohistochemistry in 60 cases of epithelial ovarian tumor tissues,20 cases of benign ovarian neoplasms and 20 cases of normal ovarian tissues,and the correlation between their expressions and clinical pathological characteristics were investigated.Results The positive expression rates of Her-2/neu in epithelial ovarian tumor tissues were significantly higher than those in normal ovarian tissues and benign ovarian neoplasms （P0.05）.The expression rate of COX-2 in ovarial cancer tissues was significantly higher than that in benign ovarian neoplasms （P0.05）,however,which was not expressed in normal ovarian tissues.Among malignant tumor groups,the expression rates of Her-2/neu at clinical Ⅲ/Ⅳ stage were significantly higher than those at clinical Ⅰ/Ⅱstage,which in lymph node metastasis group were significantly higher than those in non-lymph node group （P0.05）,and the expression of Her-2/neu was positively correlated with that of COX-2 （r=0.295,P0.05）.Conclusion The increase of expression of Her-2/neu and COX-2 in epithelial ovarian cancers may result in loss of control of cell proliferation,which can be used as the reference indexes for the diagnosis and prognostic evaluation for patients with epithelial ovarian tumors.